Latest Breaking News On - Full prescribing information - Page 4 : comparemela.com

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United statesSouth koreaPushkar muthaMariat bourlonTycel jovelle phillipsTony mokLin wangPeter robert galleCharlene mantiaMarc hoffmannEric christensonSuzanne trudelManali kirtikumar kamdarGuillermo garcia maneroMartin reckTina cascone

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSusan galbraithDave fredricksonDaiichi sankyo incDaiichi sankyo companyMerck co incAbelzeta pharmaceuticals incAmerican society of clinical oncologyAmerican societyClinical oncologyAnnual meetingRapid oral abstractExecutive vice presidentOncology business unitAbelzeta pharmaceuticals

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris

United statesSwitzerland generalSouth koreaRepublic ofNorthern irelandUnited kingdomNew zealandHong kongMartine clozelNeurocrine biosciencesJean paul clozelAlberto gimonaAndrewc weissNxera pharmaDaridorexant nxera pharmaSosei heptares

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor

Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalNorthern irelandUnited kingdomRepublic ofNew zealandSouth koreaHong kongDaridorexant simcereSosei heptaresJean yves chatelanAlberto gimonaAndrewc weissNxera pharmaDaridorexant nxera pharmaJean paul clozel

GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor

GNW-Adhoc: Idorsia announces financial results for the first quarter 2024 - advancing the company with renewed vigor
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesNorthern irelandUnited kingdomSwitzerland generalSouth koreaJean yves chatelanJean paul clozelAlberto gimonaNxera pharmaDrug administrationHead of global clinical development idorsiaIdorsia ltdEnforcement administrationEuropean unionHealth technology agencyNational institute for health